Ocugen, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ocugen, Inc. on December 10, 2019, covering events occurring on December 9, 2019. The Company is an emerging growth company incorporated in Delaware, with its common stock (OCGN) trading on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than periodic financial performance.
Material Changes and Corporate Events
- Clinical Trial Milestone: The Company announced that its Phase 3 BRAVO study for the product candidate OCU300, designed for patients with ocular Graft Versus Host Disease (oGVHD), has reached 50% enrollment.
- Capital Structure Update: As of December 9, 2019, the Company had 52,625,228 shares of common stock issued and outstanding.
- Warrant Status: There were 1,000 Series B warrants and 1,000 Series C warrants outstanding, representing less than 0.005% of the total Series B and Series C warrants issued by the Company.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of the clinical trial progress. The primary focus is the operational milestone of the Phase 3 study enrollment.
Investor Verification Checklist
- Verify the full details of the Phase 3 BRAVO study enrollment and timeline in the attached press release (Exhibit 99.1).
- Confirm the total number of Series B and Series C warrants issued to contextualize the 0.005% outstanding figure.
- Review the Company's most recent 10-K or 10-Q for comprehensive financial data, as this 8-K does not include financial statements.